MediSpend, a global leading provider of compliance and stakeholder engagement solutions for the life sciences industry, announces its acquisition of Aluc...
- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery CAS, a division of the American Chemical Soci...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services...
Christophe Beck, Ecolab’s chairman and chief executive officer, said, “The Ecolab team executed very well to deliver another strong quarter o...
Bio Usawa, a pioneering private biotechnology company committed to developing and manufacturing affordable, high‑quality monoclonal antibody therapies ...
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA&rdquo...
POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...
Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to opti...
“Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment. The agility of our o...
Group sales revenue up 6.1 percent in the first six months As expected, continued positive trend in recurring business with consumables Bioproce...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is...
© 2025 Biopharma Boardroom. All Rights Reserved.
